PharmaDrug Names Dr David Kideckel As Chairman, While SecureDose Finalizes Formulation

FULL DISCLOSURE: This content is sponsored by PharmaDrug Inc.

PharmaDrug (CSE: PHRX) this morning released a series of updates, headlined by the appointment of Dr David Kideckel to the role of Chairman of the company, who previously served as a director of the firm.

Dr Kideckel holds a Doctorate in Neuroscience and Statistics from the University of Toronto’s Institute of Medical Science, as well as an MBA from the Rotman School of Management at the University of Toronto. Having previously served in executive roles at Johnson & Johnson as well as Alexion Pharmaceuticals, the latter of which was acquired by AstraZeneca, Kideckel has two decades of experience within the biotech industry.

Most recently, Kideckel served as Managing Director, Head of Life Sciences & Senior Insititutional Equity Research Analyst at ATB Capital Markets. He’s also the founder of Kideckel Advisory Group, which provides fractional CFO and CBO services to public and private corporations.

“I believe the coming year will be transformational for PharmaDrug. As a proponent of biosynthesis and its applications through pharmaceutical manufacturing, I am excited about the work being done by SecureDose. At the same time, what initially attracted me to the Company, cepharanthine and specifically PD-001’s potential to become a multi-therapeutic agent ranging from oncology to infectious diseases, is proceeding according to plan,” commented Dr Kideckel on his appointment.

Drug development

Separately, the company also indicated this morning that SecureDose has finalized its formulation, with the next phase involving the manufacturing of a test batch. The priority for this division remains to be the development of synthetic formulations for a potential third wave of drug policy reform.

Biosynthetic formulations are now being fine tuned for scalable and economic production within pharma-grad facilities, with an announcement on the drugs of focus expected in the coming weeks, which is to be followed by the commissioning of its first test batch of product.

READ: PharmaDrug’s Sairiyo To Begin Manufacturing PD-001 For Clinical Trials In Q2

Sairiyo Therapeutics, the firms joint venture, meanwhile has initiated a regulatory and clinical development plan for the evaluation of its patented reformulated enteric coated version of orally bioavailable cepharanthine. The reformulated drug is being assessed as a potential treatment for oncology and infectious diseases under a phase 1 clinical study in Australia.

PharmaDrug last traded at $0.065 on the CSE.


FULL DISCLOSURE: PharmaDrug is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of PharmaDrug. The author has been compensated to cover PharmaDrug on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Leave a Reply

Share
Tweet
Share